Results 151 to 160 of about 6,010,235 (261)

Enteral nutritional therapy practices in pediatric hematopoietic stem cell transplant centers in Brazil. [PDF]

Hematol Transfus Cell Ther
Viau VS, da Silva AF, Poloni S, Bosa VL, Behling EB.   +4 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Association between time-to-antibiotics and clinical outcomes in neutropenic fever after hematopoietic stem cell transplant. [PDF]

Support Care Cancer
Windham SL, Guidry CA, Sung AD, Kollef MH, Simpson SQ.   +4 more
europepmc   +1 more source

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

Nurse-Led Interventions and Outcomes in Adult Hematopoietic Stem Cell Transplant Recipients: A Scoping Review. [PDF]

Nurs Rep
Muliira JK, Lazarus ER.
europepmc   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk, Afshin Shameli, Erik Ames, Jonathan R. Fromm, Bartosz Grzywacz, Min Shi, Sindhu Cherian, Jean Oak   +7 more
wiley   +1 more source

Detection of Post- Hematopoietic Stem Cell Transplant Bronchiolitis Obliterans Syndrome (BOS)-The Use of Airway Oscillometry. [PDF]

Pediatr Pulmonol
Goldfarb SB, Cooper R, Koo J, Myers KC, Walkup L, Woods J, Cook E, Hils B, Lane A, Allen J, Davies SM, Towe C.   +11 more
europepmc   +1 more source

Subset‐specific and tissue‐specific expression of NK‐cell markers and killer immunoglobulin‐like receptors: Implications for NK‐cell clonality assessment

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate immunophenotypic evaluation of natural killer (NK)‐cell neoplasms is challenging because NK‐cells lack somatically rearranged antigen receptors, are comprised of phenotypically distinct subsets, and exhibit tissue‐specific subset distribution. We developed a flow cytometry (FC) panel for NK‐cell immunophenotypic analysis and clonality
Valerie Woodings, Orrin Koepke, Jason E. Love, Alireza Torabi, Lianqun Qiu, Jonathan R. Fromm, Sindhu Cherian, Afshin Shameli   +7 more
wiley   +1 more source

State of oral innate immunity and salivary microbiome with allogeneic hematopoietic stem cell transplant. [PDF]

Microbiol Spectr
Adami GR, Fine M, Schwartz JL, Wojtowicz P, Moreira J.   +4 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source